ENKD1: A Potential Drug Target and Biomarker (G84080)

Target Name: ENKD1

NCBI ID: G84080

ENKD1

ENKD1: A Potential Drug Target and Biomarker

Enkurin domain containing 1 (ENKD1) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ENKD1 is a transmembrane protein that is expressed in various tissues and cells in the body. It plays a critical role in cell signaling and is involved in the development, maintenance, and regulation of tissues and organs.

The ENKD1 protein is composed of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is involved in cell adhesion and interaction, while the transmembrane domain is responsible for the protein's unique structure and function. The intracellular domain interacts with various intracellular signaling pathways, including the TGF-β pathway.

ENKD1 has been shown to be involved in various signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival. The TGF-β pathway is a well-established target for many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ENKD1 has been shown to play a critical role in the regulation of TGF-β signaling pathway, which suggests that it may be a potential drug target for these diseases.

In addition to its involvement in the TGF-β pathway, ENKD1 has also been shown to be involved in several other signaling pathways, including the PI3K/Akt pathway and the NF-kappa-B pathway. The PI3K/Akt pathway is involved in cell signaling and is a potential target for anti-inflammatory drugs. The NF-kappa-B pathway is involved in inflammation and immune responses and is a potential target for anti-inflammatory drugs.

ENKD1 has also been shown to be involved in the regulation of cellular processes that are important for maintaining tissue homeostasis, including cell migration, cell adhesion, and cell survival. It has been shown to play a critical role in the regulation of angiogenesis, which is the process by which new blood vessels are formed.

In conclusion, ENKD1 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its involvement in the TGF-β pathway and its ability to regulate multiple signaling pathways make it an attractive target for drug development. Further research is needed to fully understand the role of ENKD1 in disease and to develop effective treatments.

Protein Name: Enkurin Domain Containing 1

Functions: Microtubule-binding protein which regulates microtubule organization and stability (PubMed:35197565, PubMed:35072334). Promotes the stability of astral microtubules and facilitates the proper orientation of the mitotic spindle (PubMed:35197565). This allows the oriented division of basal keratinocytes and contributes to epidermal stratification (By similarity). Required for the assembly of both primary and motile cilia (PubMed:35301795). Destabilizes the interaction between CCP110 and CEP97 by competing with CEP97 for binding to CCP110 which promotes the removal of CCP110 and CEP97 from the mother centriole and allows the initiation of ciliogenesis (PubMed:35301795)

The "ENKD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ENKD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets